Blueprint Medicines

Blueprint Medicines has developed a proprietary platform that combines genomics expertise with a novel library of kinase inhibitors to enable the rapid development of potent, highly selective compounds to address clear driver genomic targets.

The library was built de novo in an iterative manner and annotated against the entire kinome; it is a proprietary resource of potent and selective tool compounds for ~200 kinases, providing high quality differentiated building blocks for medicinal chemistry programs accelerating the identification of multiple lead series for targets of interest.
Our genomics expertise enables Blueprint to identify drug targets by sequencing unexplored cancers and mining public data with new genome analysis algorithms.
Blueprint’s ability to discover and develop potent and selective kinase inhibitors against drivers of specific cancers is efficient and reproducible, and we expect to bring two or three programs to the clinic by the end of 2015.